Needham analyst Michael Matson has maintained their neutral stance on MDT stock, giving a Hold rating today.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Michael Matson’s rating is based on a mix of positive and negative indicators for Medtronic. The company’s revenue for the third quarter of fiscal year 2025 fell short of expectations, though earnings per share exceeded consensus. This mixed performance, along with a slowdown in organic growth attributed to inventory reductions in the Medical Surgical segment, contributed to a cautious outlook.
On the positive side, Medtronic’s non-GAAP gross and operating margins showed year-over-year improvement, aided by favorable currency effects. Furthermore, the company exhibited promising growth in its Cardiac Ablation Solutions and has potential growth drivers in Hugo and Symplicity Spyral for the future. These factors collectively support a Hold rating, reflecting a balanced perspective on the company’s near-term and long-term prospects.
Matson covers the Healthcare sector, focusing on stocks such as Hologic, TransMedics Group, and Atricure. According to TipRanks, Matson has an average return of -4.8% and a 40.36% success rate on recommended stocks.